Nantahala reports 148,736-share stake in Kiora
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026.
Rhea-AI Filing Summary
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Positive
- None.
Negative
- None.
Insights
Nantahala reports a modest 3.388% stake (148,736 shares), including near-term warrant exercisable shares.
The filing confirms beneficial ownership and voting/dispositive powers are shared for 148,736 shares. The inclusion of shares exercisable within sixty days is material for short-term potential conversion of warrants into common stock.
Future filings may disclose whether warrants are exercised; cash-flow treatment and timing are not provided in this excerpt.
Disclosure aligns with ownership reporting norms; shared voting and dispositive power are declared.
The Schedule 13G/A lists voting power as shared for 148,736 shares and shows no sole voting or dispositive power. This clarifies control attributes associated with the stake.
Because the position is 3.388%, it remains below the 5% threshold noted in the filing.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficial owner regulatory
warrants exercisable within sixty days financial
FAQ
What stake does Nantahala report in KPRX?
What voting and dispositive powers are disclosed for this stake?
AI-generated analysis. How Rhea-AI works. Not financial advice.